Media Highlights
FDA-Approved Rytelo a ‘Game Changer’ for Some Patients with MDS
June 17, 2024
Dr. Mikkael A. Sekeres discusses the benefits of Rytelo for adults with low- to intermediate-1 risk MDS with transfusion-dependent anemia and the unmet needs that persist in this population.
Tags: Mikkael A. Sekeres, Sylvester Comprehensive Cancer Center
